Logo

Zentalis Pharmaceuticals, Inc.

ZNTL

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of… read more

Healthcare

Biotechnology

3 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$1.55

Price

+2.39%

$0.04

Market Cap

$111.521m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$26.865m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$162.783m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$2.27

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$274.495m

$351.707m

Assets

$77.212m

Liabilities

$37.690m

Debt
Debt to Assets

10.7%

-0.2x

Debt to EBITDA
Free Cash Flow

-$151.091m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases